< Back to previous page
Researcher
Dirk Jochmans
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Sep 2010 → Today
Projects
1 - 5 of 5
- Prohylaxis of at risks persons with an ultrapotent SARS-CoV-2 neutralizing antibody.From20 May 2020 → 21 May 2021Funding: FWO thematic call for applied research
- Optimize viral replication in primary human airway epithelial (HAE) cells for use in antiviral research to combat respiratory viral infectionsFrom22 Sep 2019 → 22 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Organoids for Virus Research - An innovative training-ETN programmeFrom1 Jan 2019 → 31 Dec 2022Funding: H2020-EU.1.3.- EXCELLEN SCIENCE - Marie Skłodowska-Curie actions
- Development and mechanism of action of novel inhibitors of rabies virus replication.From17 Sep 2018 → 17 Sep 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Towards a combined post-exposure prophylaxis and successful treatment of rabies in humansFrom1 Oct 2017 → 30 Sep 2020Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 101
- Mechanism of action of phthalazinone derivatives against rabies virus.(2024)
Authors: Dirk Jochmans, Johan Neyts
Pages: 105838 - Design, synthesis, and molecular modeling studies of novel 2-quinolone-1,2,3-triazole-α-aminophosphonates hybrids as dual antiviral and antibacterial agents.(2024)
Authors: Johan Neyts, Dirk Jochmans, Steven De Jonghe
Pages: 116235 - Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted(2024)
Authors: Dirk Jochmans, Rana Abdelnabi, Birgit Weynand, Johan Neyts
- Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters(2024)
Authors: Dirk Jochmans, Johan Neyts
Pages: 172 - 178 - A Robust Phenotypic High-Throughput Antiviral Assay for the Discovery of Rabies Virus Inhibitors(2023)
Authors: Johan Neyts, Dirk Jochmans
- Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.(2023)
Authors: Steven De Jonghe, Kim Donckers, Dirk Jochmans, Johan Neyts
Pages: eabo7201 - Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411(2023)
Authors: Dirk Jochmans, Johan Neyts
- Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects(2023)
Authors: Dirk Jochmans, Johan Neyts, Steven De Jonghe, Pieter Leyssen
- Synthesis of new 3-acetyl-1,3,4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents(2023)
Authors: Johan Neyts, Dirk Jochmans, Graciela Andrei, Robert Snoeck
Pages: 2147 - 2159 - Antiviral strategies for epidemic and pandemic preparedness(2023)
Authors: Dirk Jochmans, Manon Laporte, Johan Neyts
Pages: 856 - 860
Patents
1 - 5 of 5
- Design synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity (Inventor)
- Antiviral compounds (Inventor)
- Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity (Inventor)
- Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity (Inventor)
- Design synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity (Inventor)